Why Mittleman Brothers Bullish On HC2 Holdings (HCHC)
Published on August 17, 2018 at 6:20 am by
M.Nadeem
in News
Share
New York-based Mittleman Brothers recently released its Q2 investor letter in which the firm discussed its investment thesis on HC2 Holdings Inc (NYSE: HCHC) and other companies. We have already covered Mittleman’s viewpoint about AMC Entertainment and in this article we are going to focus on the firm’s thoughts on HC2 Holdings. Here is what Christopher Mittleman, chief investment officer and managing partner of Mittleman Brothers, said about HCHC in the letter.
HC2 Holdings (HCHC) on May 2nd announced the sale of BeneVir BioPharm, a developmental-stage biotech company focusing on oncolytic viral immunotherapy, in which HC2 held a 76% stake. HC2 paid just $8M for its stake in BeneVir, which we were using in our estimates of NAV. This transaction provided a net of $85M in cash at closing to HC2, plus additional contingent payments of up to $900M based on achievement of certain predetermined milestones. The up-front cash component alone increased HC2’s NAV by nearly $2/share (raising our estimate from $10 to $12/share), without handicapping the likelihood of the future milestone payments coming in from the acquirer, Janssen (a pharmaceutical company owned by Johnson & Johnson).
To put into perspective the full value creation that would take place in the event those milestones were achieved, $900M represents an additional $17 per share in value to HCHC holders (vs. a current price of $5.85), the receipt of which would be spread out over many years.
We believe there are additional monetization opportunities within HC2’s business mix, of similar or greater size than Benevir. Management has also expressed their intent to lower their cost of capital through a global refinancing of their $510M of 11% debt due 12/1/19, which should produce significant savings on interest expense, and possibly allow for share buybacks. We are optimistic that investors will soon begin to appreciate that the current NAV, coupled with the significant upside of many of its holdings, warrants a much higher stock price.
yuttana Contributor Studio/Shutterstock.com
New York-based HC2 Holdings Inc (NYSE: HCHC) is a holding company whose subsidiaries are focused on construction, marine services, energy, telecommunications, life sciences, broadcasting, insurance and other businesses. The company has a market cap of around $278 million. HC2’s main operating subsidiaries include DBM Global, a family of companies providing fully-integrated structural and steel construction services, and Global Marine Systems, a provider of engineering and underwater services on submarine cables.
Shares HC2 Holdings are up 3.47% since the beginning of this year. Over the past three months, the stock has moved up 2.96% while the share price has jumped 38.80% over the past 12 months.
HCHC isn’t a very popular stock among hedge funds tracked by Insider Monkey. As of the end of the fourth quarter of 2017, there were 12 funds in our database holding shares of the company.
When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.
Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.
At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.
Do the math. According to Musk, this technology could be worth $250 trillion by 2040.
Put another way, that’s roughly equal to:
175 Teslas
107 Amazons
140 Metas
84 Googles
65 Microsofts
And 55 Nvidias
And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.
It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.
Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.
How could anything be worth that much?
The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.
And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.
What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.
In fact, Verge argues this company’s supercheap AI technology should concern rivals.
Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.
Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.
When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.
Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…
But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.
And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…
This prediction might not be bold at all:
A few years from now, you’ll wish you’d owned this stock.
The best part? You can discover everything about this company and its groundbreaking technology right now.
I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.
Trust me — you’ll want to read this report before putting another dollar into any tech stock.
For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!
Here’s why this is a deal you can’t afford to pass up:
• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.
• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.
• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149
• Bonus Reports: Premium access to members-only fund manager video interviews
• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
• 30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.
If you’re thinking about getting in, don’t wait – because once Wall Street catches wind of this story, the easy money will be gone.
Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.
Here’s what to do next:
1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99 a month.
2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.
3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.
Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!
